|Day Low/High||2.10 / 2.15|
|52 Wk Low/High||1.18 / 2.49|
MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc.
Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation Had Successful PreNDA meeting with FDA for TADFIN...
MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Veru Inc.
MIAMI, July 18, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced the dismissal of litigation...
-- Provides $2.4 Million for Drug Product Development --
Immediate Non-Dilutive Financing to Further Drug Development
Veru Remains on Schedule to File 505(b)(2) Tamsulosin DRS New Drug Application in First Half Calendar 2018
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.